Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 652-660

  Rosso, Leonardo Gómez ^a,b   Lhomme, Marie ^a,c,d,e   Meroño, Tomas ^b   Sorroche, Patricia ^f   Catoggio, Luis ^f   Soriano, Enrique ^f   Saucedo, Carla ^f   Malah, Verónica ^g   Dauteuille, Carolane ^a,c,d   Boero, Laura ^b   Lesnik, Philippe ^a,c,d   Robillard, Paul ^a,c,d   John Chapman, M ^a,c,d   Brites, Fernando ^b   Kontush, Anatol ^a,c,d  

^a INSERM   (France)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ICAN   (France)

^f School of Medicine   (Argentina)

^g HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Antioxidative activity; Cardiovascular disease; Dysfunction; HDL; Inflammation; Rheumatoid arthritis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPIDOME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE D; SERUM AMYLOID A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; OXIDATIVE STRESS; POSTMENOPAUSE; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84910024203     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.034     Document Type: Article

References (50)

1. Gabriel S.E Cardiovascular morbidity and mortality in rheumatoid arthritis Am J Med Oct 2008, 121(10 Suppl.1):S9-S14.
2. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies Ann Rheum Dis Sep 2012, 71(9):1524-1529.
3. Jacobsson L.T., Knowler W.C., Pillemer S., et al Rheumatoid arthritis and mortality A longitudinal study in Pima Indians Arthritis Rheum Aug 1993, 36(8):1045-1053.
4. Semb A.G., Kvien T.K., Aastveit A.H., et al Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISK (AMORIS) Study Ann Rheum Dis Nov 2010, 69(11):1996-2001.
5. Gabriel S.E., Crowson C.S., Kremers H.M., et al Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years Arthritis Rheum Jan 2003, 48(1):54-58.
6. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors Arthritis Rheum Dec 2001, 44(12):2737-2745.
7. Hahn B.H., Grossman J., Ansell B.J., Skaggs B.J., McMahon M Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis Arthritis Res Ther 2008, 10(4):213.
8. Onat A., Direskeneli H Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy Curr Pharm Des 2012, 18(11):1465-1477.
9. Navab M., Reddy S.T., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M The role of dysfunctional HDL in atherosclerosis J.Lipid Res Apr 2009, 50(Suppl.l):S145-S149.
10. Camont L., Chapman M.J., Kontush A Biological activities of HDL subpopulations and their relevance to cardiovascular disease Trends Mol Med Oct 2011, 17(10):594-603.
11. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function Arterioscler Thromb Vasc Biol Jun 2009, 29(6):870-876.
12. Kontush A., Therond P., Zerrad A., et al Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities Arterioscler Thromb Vasc Biol Aug 2007, 27(8):1843-1849.
13. Kontush A., Chapman M.J High-density Lipoproteins: Structure, Metabolism, Function and Therapeutics 2012, Wiley & Sons, New York.
14. Camont L., Lhomme M., Rached F., et al Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities Arterioscler Thromb Vasc Biol Dec 2013, 33(12):2715-2723.
15. Arnett F.C., Edworthy S.M., Bloch D.A., et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum Mar 1988, 31(3):315-324.
16. (WHO) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Report of WHO Consultation Part I: Diagnosis and Classification of Diabetes Mellitus 1999, World Health Organization, Geneva.
17. Hansel B., Giral P., Nobecourt E., et al Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity J.Clin Endocrinol Metab Oct 2004, 89(10):4963-4971.
18. Nobecourt E., Jacqueminet S., Hansel B., et al Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia Diabetologia Mar 2005, 48(3):529-538.
19. Kontush A., de Faria E.C., Chantepie S., Chapman M.J Anormotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity Atherosclerosis Oct 2005, 182(2):277-285.
20. Ridker P.M., Cook N Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores Circulation Apr 27 2004, 109(16):1955-1959.
21. Peters M.J., Voskuyl A.E., Sattar N., Dijkmans B.A., Smulders Y.M., Nurmohamed M.T The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better Int J Clin Pract Sep 2010, 64(10):1440-1443.
22. Graf J., Scherzer R., Grunfeld C., Imboden J Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis PloS One 2009, 4(7):e6242.
23. Rumsey S.C., Galeano N.F., Arad Y., Deckelbaum R.J Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins J.Lipid Res Oct 1992, 33(10):1551-1561.
24. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., Motulsky A.G Spectrophotometric assays for the enzymatic-hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase arylesterase Anal Biochem Aug 1 1989, 180(2):242-247.
25. Blank M.L., Hall M.N., Cress E.A., Snyder F Inactivation of 1-alkyl-2-acetyl-Sn-glycero-3-phosphocholine by a plasma acetylhydrolase - higher activities in hypertensive rats Biochem Biophys Res Commun 1983, 113(2):666-671.
26. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M Adensity gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum J.Lipid Res Feb 1981, 22(2):339-358.
27. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia Arterioscler Thromb Vasc Biol Jun 1996, 16(6):763-772.
28. Guerin M., Egger P., Soudant C., et al Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux Atherosclerosis Aug 2002, 163(2):287-296.
29. Mackness M.I Human serum paraoxonase is inhibited in EDTA plasma Biochem Biophys Res Commun Jan 14 1998, 242(2):249.
30. Kontush A., Chantepie S., Chapman M.J Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress Arterioscler Thromb Vasc Biol Oct 1 2003, 23(10):1881-1888.
31. de Souza J.A., Vindis C., Hansel B., et al Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity Atherosclerosis Mar 2008, 197(1):84-94.
32. Crowson C.S., Therneau T.M., Davis J.M., Roger V.L., Matteson E.L., Gabriel S.E Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis Arthritis Rheum Oct 2013, 65(10):2562-2566.
33. Robertson J., Peters M.J., McInnes I.B., Sattar N Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm Nat Rev Rheumatol Sep 2013, 9(9):513-523.
34. Bisoendial R.J., Stroes E.S., Kastelein J.J., Tak P.P Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins Nat Rev Rheumatol Mar 2010, 6(3):157-164.
35. Deeg M.A., Bierman E.L., Cheung M.C GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex J.Lipid Res Mar 2001, 42(3):442-451.
36. O'Brien K.D., Pineda C., Chiu W.S., Bowen R., Deeg M.A Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes Circulation Jun 8 1999, 99(22):2876-2882.
37. Raymond F.D., Fortunato G., Moss D.W., Castaldo G., Salvatore F., Impallomeni M Inositol-specific phospholipase D activity in health and disease Clin Sci (Lond.) Apr 1994, 86(4):447-451.
38. Fournier N., Paul J.L., Atger V., et al HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum Arterioscler Thromb Vasc Biol Nov 1997, 17(11):2685-2691.
39. Gelissen I.C., Harris M., Rye K.A., et al ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I Arterioscler Thromb Vasc Biol Mar 2006, 26(3):534-540.
40. McMahon M., Grossman J., FitzGerald J., et al Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis Arthritis Rheum Aug 2006, 54(8):2541-2549.
41. Ronda N., Favari E., Borghi M.O., et al Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus Ann Rheum Dis Mar 2014, 73(3):609-615 10.1136/annrheumdis-2012-202914.
42. Charles-Schoeman C., Lee Y.Y., Grijalva V., et al Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis Ann Rheum Dis Jul 2012, 71(7):1157-1162.
43. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., et al Inflammation impairs reverse cholesterol transport invivo Circulation Mar 3 2009, 119(8):1135-1145.
44. Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort Arthritis Rheum Aug 2005, 52(8):2293-2299.
45. Myasoedova E., Crowson C.S., Kremers H.M., et al Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease Ann Rheum Dis Mar 2011, 70(3):482-487.
46. Charles-Schoeman C., Watanabe J., Lee Y.Y., et al Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis Arthritis Rheum Oct 2009, 60(10):2870-2879.
47. Zerrad-Saadi A., Therond P., Chantepie S., et al HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis Arterioscler Thromb Vasc Biol Dec 2009, 29(12):2169-2175.
48. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., de Beer F.C Serum amyloid A-containing human high density lipoprotein 3 Density, size, and apolipoprotein composition J.Biol Chem Jul 25 1986, 261(21):9644-9651.
49. Cabana V.G., Lukens J.R., Rice K.S., Hawkins T.J., Getz G.S HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease J.Lipid Res Dec 1996, 37(12):2662-2674.
50. Watanabe J., Charles-Schoeman C., Miao Y., et al Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis Arthritis Rheum Jun 2012, 64(6):1828-1837.